Landmark Alliance ATOMIC Trial Establishes New Standard of Care for Patients with Stage III dMMR Colon Cancer

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery. The phase III Alliance ATOMIC A021502 trial, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of th


UPCOMING MEETINGS

Upcoming Group Meetings
- May 13-15, 2026    Registration   Meeting Schedule 
- November 4-6, 2026 

All meetings will be held at the Loews Chicago O'Hare Hotel in Rosemont, IL and are open to all Alliance members.
 

IN THE NEWS


ALLIANCE ON SOCIAL

FROM THE NCI